References
- Yoon JH, Lee JS, Yong SW, et al. Endothelial dysfunction and hyperhomocysteinemia in Parkinson’s disease: flow-mediated dilation study. Mov Disord. 2014;29:1551–1555.10.1002/mds.26005
- Chambers JC, Obeid OA, Kooner JS. Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. Arterioscler Thromb Vasc Biol. 1999;19:2922–2927.10.1161/01.ATV.19.12.2922
- Dorszewska J, Florczak J, Rozycka A, et al. Oxidative DNA damage and level of thiols as related to polymorphisms of MTHFR, MTR, MTHFD1 in Alzheimer’s and Parkinson’s diseases. Acta Neurobiol Exp (Wars). 2007;67:113–129.
- Dorszewska J, Prendecki M, Lianeri M, et al. Molecular effects of L-dopa therapy in Parkinson’s disease. Curr Genomics. 2014;15:11–17.10.2174/1389202914666131210213042
- Dorszewska J, Prendecki M, Oczkowska A, et al. Polymorphism of the COMT, MAO, DAT, NET and 5-HTT genes, and biogenic amines in Parkinson’s disease. Curr Genomics. 2013;14:518–533.
- Zhang W, Li P, Geng Q, et al. Simultaneous determination of glutathione, cysteine, homocysteine, and cysteinylglycine in biological fluids by ion-pairing high-performance liquid chromatography coupled with precolumn derivatization. J Agric Food Chem. 2014;62:5845–5852.10.1021/jf5014007
- Cadet JL, Jayanthi S, McCoy MT, et al. Dopamine D1 receptors, regulation of gene expression in the brain, and neurodegeneration. CNS Neurol Disord Drug Targets. 2010;9:526–538.10.2174/187152710793361496
- Wood M, Dubois V, Scheller D, et al. Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors. Br J Pharmacol. 2015;172:1124–1135.10.1111/bph.2015.172.issue-4
- Sabens EA, Distler AM, Mieyal JJ. Levodopa deactivates enzymes that regulate Thiol−Disulfide homeostasis and promotes neuronal cell—death: implications for therapy of Parkinson’s disease. Biochemistry. 2010;49:2715–2724.10.1021/bi9018658
- Müller T. Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson’s disease. Expert Rev Neurother. 2013;13:707–718.10.1586/ern.13.50
- Cawello W, Braun M, Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos. 2009;37:2055–2060.10.1124/dmd.109.027383
- Elshoff JP, Cawello W, Andreas JO, et al. An update on pharmacological, pharmacokinetic properties and drug–drug interactions of rotigotine transdermal system in Parkinson’s disease and restless legs syndrome. Drugs. 2015;75:487–501.10.1007/s40265-015-0377-y
- Gupta H, Babu RJ. Transdermal delivery: product and patent update. Recent Pat Drug Deliv Formul. 2013;7:184–205.10.2174/187221130703131128121747
- Müller T, Muhlack S. Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson’s disease patients. J Neural Transm. 2014;121:643–648.10.1007/s00702-013-1155-1